Nicotinamide riboside enhances adoptive T cell therapy by promoting memory differentiation and metabolic fitness
Nengzhi Pang, Jinping He, Lei Pei, Ying Xiao, Yingying Gu, Cheng Zhi, Xuye Lai, Mingtao Chen, Qiyao Xiao, Xueqian Wu, Zhenfeng Zhang, Lili Yang · 2026
Read Nicotinamide riboside enhances adoptive T cell therapy by promoting memory differentiation and metabolic fitness by Nengzhi Pang, Jinping He, Lei Pei, Ying Xiao, Yingying Gu, Cheng Zhi, Xuye Lai, Mingtao Chen, Qiyao Xiao, Xueqian Wu, Zhenfeng Zhang, Lili Yang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13464305.txt.
Description
Nengzhi Pang and colleagues tested a vitamin-like compound in 2026 to strengthen transferred killer T cells against liver cancer. Adoptive T cell therapy works only as well as the cells' stamina, which rests on their mitochondria, the cell's power units. Nicotinamide riboside, known to boost mitochondrial health, was tried with CD8 T cells in mouse liver cancer models.
Treated cells formed more central memory cells, switched on memory genes such as Tcf7, Ccr7, and Foxo1, and recalled attacks more strongly with better energy use and cytokine output. Blocking Foxo1 partly undid the gains, tying the benefit to that gene program. The compound may serve as a safe metabolic helper for liver cancer cell therapy, pending human testing.
Catalog record
| CREATOR | Nengzhi Pang, Jinping He, Lei Pei, Ying Xiao, Yingying Gu, Cheng Zhi, Xuye Lai, Mingtao Chen, Qiyao Xiao, Xueqian Wu, Zhenfeng Zhang, Lili Yang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |